Compounded tirzepatide compared with Zepbound and Mounjaro

One molecule, two brand names

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1. Eli Lilly markets it as Mounjaro for blood sugar control in type 2 diabetes and as Zepbound for chronic weight management. Zepbound's label also covers moderate to severe obstructive sleep apnea in adults with obesity.

Both brands are given as a once-weekly injection under the skin. The Zepbound label lists single-dose pens, single-dose vials and multi-dose pens, all for subcutaneous use only. The trials on these labels tested the branded products.

What compounded tirzepatide is

A compounded tirzepatide injection is prepared by a licensed pharmacy from a prescription written for you. The FDA says compounded drugs are not FDA-approved and that the agency does not review them for safety, effectiveness or quality before they reach patients. They are not generics of Zepbound or Mounjaro, and no large trial has tested a compounded tirzepatide product.

Most compounding is done in state-licensed 503A pharmacies, overseen mainly by state boards of pharmacy. Outsourcing facilities registered under section 503B are inspected by the FDA and must follow federal manufacturing standards.

The shortage ended in December 2024

Compounders were able to make tirzepatide widely while it was on the FDA drug shortage list. In a declaratory order dated December 19, 2024, the FDA determined the tirzepatide injection shortage was resolved.

The agency set short wind-down periods: state-licensed pharmacies and physicians had until February 18, 2025, and outsourcing facilities until March 19, 2025. After that, the shortage no longer justified compounding copies of the approved product. A compounded preparation now needs to be tied to an individual patient's documented clinical need, and rules continue to change, so your pharmacy must confirm it can lawfully dispense.

What the FDA has reported

As of May 31, 2026, the FDA had received more than 730 adverse event reports involving compounded tirzepatide, and it says such reports are likely undercounted. With compounded GLP-1s generally, the agency has described dosing errors from measuring doses out of vials, and prescribing at doses or step-up speeds beyond the approved label.

The FDA has also flagged fake or falsely labeled tirzepatide sold online and products marked "for research use only" sold for people. Only use a product prescribed by a licensed clinician and dispensed by a licensed pharmacy you can name.

Safety is shared across every version

The Zepbound label carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it does in people. It must not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia type 2 (MEN 2).

Nausea, diarrhea, vomiting and constipation are common. Other warnings include pancreatitis, gallbladder disease, kidney injury from dehydration and low blood sugar with insulin or sulfonylureas. Tirzepatide can make birth control pills less reliable, so the label advises a non-oral or backup method for four weeks after starting and after each dose increase. It should not be used in pregnancy, and it should not be combined with any other GLP-1 or tirzepatide product.

Choosing between them

If you can access Zepbound and it suits you, an FDA-approved product is a reasonable first choice. HealifyMD offers a weight loss membership from $75/month for members who get branded GLP-1s through their own coverage or pharmacy.

If your clinician decides a compounded preparation is appropriate for you, compounded tirzepatide through HealifyMD is from $399/month, or $750 for 2 months ($375/month). Your price is confirmed at the eligibility review, labs are priced separately and care is offered only in states where our clinicians are licensed. Whichever route you take, we will not describe a compounded product as equivalent to Zepbound.

What care looks like with either version

Tirzepatide is started at a low dose and raised in steps, so your stomach has time to adjust. Your clinician decides when, or whether, to move up based on how you feel and how your weight, blood pressure and blood sugar respond.

Follow-up matters as much as the medicine. Expect check-ins about nausea, hydration, protein intake and strength training to protect muscle, and a clear plan agreed in advance for what happens if you need to pause, miss doses or stop.

Before you fill any tirzepatide prescription

• Check the label says whether the product is compounded or FDA-approved.
• Know the name of the dispensing pharmacy and that it is licensed in your state.
• Ask how the dose is measured and get clear instructions for your syringe or pen.
• Never stack tirzepatide with semaglutide or another GLP-1.
• Agree on a step-up plan with your clinician rather than raising the dose on your own.